Type1diabetes Clinical Trial
Official title:
A Double-blinded, Randomized, Parallel, Placebo-controlled Trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents
This is a combined phase 1 and 2 study in 66 subjects, male or female, between 7-21 years of age that have recently (< 6 months) been diagnosed with type 1 diabetes. The first phase 1 part of the study includes six subjects openly receiving allogeneic Wharton's jelly derived mesenchymal stromal cells as the Advanced Therapy Medicinal Product (ATMP) Protrans, three each in the age ranges 7-11 and 12-18.The second part is a randomized, double-blinded placebo-controlled phase 2 study in parallel design comparing allogeneic Wharton's jelly derived mesenchymal stromal cells treatment (as Protrans) to placebo in children and adolescent subjects (7-21 years of age) diagnosed with type 1 diabetes, The primary objectives of this study will be to investigate the safety, tolerance and efficacy after an allogieneic infusion of Wharton's jelly derived mesenchymal stromal cells.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | December 2028 |
Est. primary completion date | September 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 21 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent for participation of the study (for subjects below 18 years of age also from both caregivers), given before undergoing any study-specific procedures 2. Clinical history compatible with type 1 diabetes diagnosed less than 6 months before enrolment 3. In the first part of the study, six subjects, three between 7-11 and three between 12-18 years of age (both groups inclusive at both ends), will be included. The sixty subjects in the second part of the study are stratified by age (12-21 and 7-11 years, respectively) and randomized to one of two treatment arms (active or placebo), with a 6-month safety delay for the younger stratum. 4. Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol. 5. Fasting plasma C-peptide concentration >0.12 nmol/L. 6. Subjects of child-bearing potential must agree to using adequate contraception until one year after the administration of WJMSC/Placebo. Adequate contraception is as follows: 1. oral (except low-dose gestagen (lynestrenol and noretisteron), injectable or implanted hormonal contraceptives. 2. intrauterine device 3. intrauterine system (for example progestin-releasing coil) 4. vasectomized male (with appropriate postvasectomy documentation of the absence of sperm in the ejaculate) Exclusion Criteria: 1. Subjects with body weight >100 kg 2. Subjects with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris. 3. Subjects with uncontrolled hypertension (=160/105 mmHg). 4. Subjects with active on-going infections. 5. Subjects with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has traveled in areas with a high risk of tuberculosis or mycosis within the last 3 months. 6. Subjects with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (subjects with serology consistent with previous vaccination and a history of vaccination are acceptable), or hepatitis C. 7. Subjects with any systemic immune suppressive treatment 8. Subjects with a known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease. 9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 10. Subjects with known, or previous, malignancy. 11. Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin. 12. Subjects with GFR <60 ml/min/1.73 m2 body surface. 13. Subject with any condition or any circumstance that, in the opinion of the investigator, would make it unsafe to undergo treatment with MSC. 14. Known hypersensitivity against any excipients, i.e., dimethyl sulfoxide (DMSO). |
Country | Name | City | State |
---|---|---|---|
Sweden | Uppsala University Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Uppsala University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Gender differences | Differences in parameters of primary and secondary endpoints between genders | 6 months | |
Other | Gender differences | Differences in parameters of primary and secondary endpoints between genders | 12 months | |
Other | HLA class 1 genotypes | Differences in parameters of primary and secondary endpoints between HLA class 1 genotypes | 6 months | |
Other | HLA class 1 genotypes | Differences in parameters of primary and secondary endpoints between HLA class 1 genotypes | 12 months | |
Other | age | Differences in parameters of primary and secondary endpoints between ages 7-11 and 12-21 | 6 months | |
Other | age | Differences in parameters of primary and secondary endpoints between ages 7-11 and 12-21 | 12 months | |
Other | Autoantibodies | Change of levels of diabetes-related autoantibodies when compared to test before the start of treatment (baseline) | 6 months | |
Other | Autoantibodies | Change of levels of diabetes-related autoantibodies when compared to test before the start of treatment (baseline) | 12 months | |
Other | Peripheral blood mononuclear cells | Change in reactivity and cytokine production of peripheral blood mononuclear cells when compared to test before the start of treatment (baseline) | 6 months | |
Other | Peripheral blood mononuclear cells | Change in reactivity and cytokine production of peripheral blood mononuclear cells when compared to test before the start of treatment (baseline) | 12 months | |
Primary | Safety at one year evaluated as adverse events | Safety parameters will be evaluated at each study visit and recorded as adverse events. | One year | |
Primary | Safety at five years evaluated as adverse events | Safety parameters will be evaluated at each study visit and recorded as adverse events. | Five years | |
Primary | Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test. | Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 12 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline). | One year | |
Secondary | Insulin independency | The proportion of study participants independent of insulin at 6 months | One year | |
Secondary | Insulin independency | The proportion of study participants independent of insulin at 12 months | One year | |
Secondary | Low insulin needs | The proportion of study participants with daily insulin needs <0.25 U/kg at 6 months | 6 months | |
Secondary | Low insulin needs | The proportion of study participants with daily insulin needs <0.25 U/kg at 12 months | 12 months | |
Secondary | Insulin needs | Insulin requirement/kg body weigh at 6 months | 6 months | |
Secondary | Insulin needs | Insulin requirement/kg body weigh at 12 months | 12 months | |
Secondary | HbA1c | HbA1c at 6 months | 6 months | |
Secondary | HbA1c | HbA1c at 12 months | 12 months | |
Secondary | Time in target | Time in target (4-8 mmol/l) as measured by flash glucose monitoring for 14 days at 6 months | 6 months | |
Secondary | Time in target | Time in target (4-8 mmol/l) as measured by flash glucose monitoring for 14 days at 12 months | 12 months | |
Secondary | Time in range | Time in target (3.9-10 mmol/l) as measured by flash glucose monitoring for 14 days at 6 months | 6 months | |
Secondary | Time in range | Time in target (3.9-10 mmol/l) as measured by flash glucose monitoring for 14 days at 12 months | 12 months | |
Secondary | C-peptide | Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 6 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline). | 6 months | |
Secondary | Change in peak C-peptide | Change in peak C-peptide concentration during the first 6 months | 6 months | |
Secondary | Change in peak C-peptide | Change in peak C-peptide concentration during the first 12 months | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03886974 -
Transition to Adult Care in Type 1 Diabetes
|
||
Completed |
NCT05620251 -
Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
|
||
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05078658 -
Low-carbohydrate Diet in Children With Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06018324 -
CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
|
||
Withdrawn |
NCT03736083 -
Introducing CGM at Type 1 Diabetes Diagnosis
|
N/A | |
Completed |
NCT03177096 -
Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes
|
N/A | |
Completed |
NCT04172077 -
Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
|
||
Recruiting |
NCT04950634 -
Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
|
||
Completed |
NCT04450745 -
Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients
|
N/A | |
Completed |
NCT03165786 -
A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
|
N/A | |
Terminated |
NCT04028960 -
IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
|
Phase 2 | |
Recruiting |
NCT05324488 -
Diabetes Registry Graz for Biomarker Research
|
||
Completed |
NCT02984709 -
Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes
|
N/A | |
Completed |
NCT02984514 -
Brown Adipose Tissue in Type 1 Diabetes
|
N/A | |
Recruiting |
NCT06372392 -
Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps
|
N/A | |
Recruiting |
NCT03311516 -
New Insulin Therapy by Multiwave Bolus
|
N/A | |
Recruiting |
NCT05973799 -
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
|
N/A | |
Completed |
NCT03711656 -
Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques
|
N/A | |
Recruiting |
NCT05737654 -
The Effect of Exercise on Metabolic Parameters, Anthropometric Measurement Values and Quality of Life
|
N/A |